scholarly journals Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials

2012 ◽  
Vol 21 (2) ◽  
pp. 565-573 ◽  
Author(s):  
Luigi Celio ◽  
Erminio Bonizzoni ◽  
Emilio Bajetta ◽  
Silvia Sebastiani ◽  
Tania Perrone ◽  
...  
Keyword(s):  
Single Dose ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Patient Data ◽  
Nausea And Vomiting ◽  
Phase Iii ◽  
Two Phase ◽  
Phase Iii Trials ◽  
Effect Of Age

Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials

2017 ◽  
Vol 35 (6) ◽  
pp. 622-628 ◽  
Author(s):  
Richard Jackson ◽  
Eftychia-Eirini Psarelli ◽  
Sarah Berhane ◽  
Harun Khan ◽  
Philip Johnson
Keyword(s):  
Hepatocellular Carcinoma ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Hepatocellular Cancer ◽  
Standard Of Care ◽  
Exponential Model ◽  
Patient Data ◽  
Phase Iii ◽  
Disease Etiology ◽  
Hazard Ratios

Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear. To address this, we undertook an individual patient data meta-analysis of three large prospective randomized trials in which sorafenib was the control arm. Methods Of a total of 3,256 patients, 1,643 (50%) who received sorafenib were available. The primary end point was overall survival (OS). A Bayesian hierarchical approach for individual patient data meta-analyses was applied using a piecewise exponential model. Results are presented in terms of hazard ratios comparing sorafenib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status. Results Hazard ratios show improved OS for sorafenib in patients who are both HBV negative and HCV positive (log [hazard ratio], −0.27; 95% CI, −0.46 to −0.06). Median unadjusted survival is 12.6 (11.15 to 13.8) months for sorafenib and 10.2 (8.88 to 12.2) months for “other” treatments in this subgroup. There was no evidence of improvement in OS for any other patient subgroups defined by HBV and HCV. Results were consistent across all trials with heterogeneity assessed using Cochran’s Q statistic. Conclusion There is consistent evidence that the effect of sorafenib on OS is dependent on patients’ hepatitis status. There is an improved OS for patients negative for HBV and positive for HCV when treated with sorafenib. There was no evidence of any improvement in OS attributable to sorafenib for patients positive for HBV and negative for HCV.

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

2021 ◽  
Vol 147 (2) ◽  
pp. AB56
Author(s):  
Mark Liu ◽  
Camille Taillé ◽  
Jason Lee ◽  
Steven Smith ◽  
Steve Mallett ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Phase Iii ◽  
Two Phase ◽  
Phase Iii Trials ◽  
Post Hoc ◽  
Clinical Asthma
Sign in / Sign up

Export Citation Format

Share Document